{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:28:58Z","timestamp":1794086938641,"version":"4.8.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vertex Pharmaceuticals Incorporated","award":["Vertex Pharmaceuticals Incorporated"],"award-info":[{"award-number":["Vertex Pharmaceuticals Incorporated"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study aimed to compare the psychometric performance of the Cystic Fibrosis Questionnaire\u2013Revised\u20138 Dimensions (CFQ-R-8D), a new, condition-specific, preference-based measure, with that of generic preference-based measures EQ-5D-3L and Short Form 6 dimensions (SF-6D).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from three trials of participants with CF aged\u2009\u2265\u200914 years who completed the CFQ-R and EQ-5D-3L or SF-6D were used. Analyses were undertaken to evaluate convergent validity based on correlations with CFQ-R domain scores. Known-group validity was assessed based on percent predicted forced expiratory volume in one second and pulmonary exacerbations. Responsiveness was based on correlation of change and sensitivity to change based on change in symptom severity. Effect sizes and standardized response means were estimated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CFQ-R-8D utilities and dimensions were strongly correlated with most of the overlapping CFQ-R domain scores (\u03c1\u2009&gt;\u20090.5); EQ-5D-3L and SF-6D utilities and dimensions had moderate (\u03c1\u2009&gt;\u20090.3) to strong correlations in dimensions capturing similar concepts. All measures showed evidence of known-group validity (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Change correlations were strong for CFQ-R-8D utilities and dimensions and CFQ-R, but they were moderate for SF-6D and mostly weak ((\u03c1\u2009&gt;\u20090.1) for EQ-5D-3L. The SF-6D had the largest mean change over time and effect sizes, followed by CFQ-R-8D and then EQ-5D-3L. Neither CFQ-R-8D or SF-6D utility scores had ceiling effects (&lt;\u20099% responses in full health) compared with those of EQ-5D-3L (61-62%). In participants classified as being in full health by EQ-5D-3L, CFQ-R-8D captured CF-specific health problems, particularly cough, abdominal pain, and breathing difficulty.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The CFQ-R-8D reflected known-group differences and changes over time with stronger evidence of good psychometric performance than EQ-5D-3L and similar evidence as SF-6D. Additionally, the CFQ-R-8D captured more condition-specific symptoms than EQ-5D-3L or SF-6D, which are important determinants of health-related quality of life for people with CF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00697-w","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T08:02:17Z","timestamp":1709107337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-1481","authenticated-orcid":false,"given":"Clara","family":"Mukuria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Rowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Acaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyue","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Sosnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Quittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"697_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1477-7525-1-80","volume":"1","author":"L Prieto","year":"2003","unstructured":"Prieto L, Sacristan JA (2003) Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes 1:80","journal-title":"Health Qual Life Outcomes"},{"key":"697_CR2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095\u20131108","journal-title":"Med Care"},{"key":"697_CR3","volume-title":"EQ-5D-3L user guide","author":"EuroQol Research Foundation","year":"2018","unstructured":"EuroQol Research Foundation (2018) EQ-5D-3L user guide. EuroQol Research Foundation, Rotterdam, the Netherlands"},{"key":"697_CR4","unstructured":"National Institute for Health and Care Excellence (2013) Guide to the methods of technology appraisal 2013"},{"key":"697_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10198-017-0902-x","volume":"19","author":"AP Finch","year":"2018","unstructured":"Finch AP, Brazier JE, Mukuria C (2018) What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews. Eur J Health Econ 19:557\u2013570","journal-title":"Eur J Health Econ"},{"key":"697_CR6","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS (2016) Cystic fibrosis. Lancet 388:2519\u20132531","journal-title":"Lancet"},{"key":"697_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12955-016-0465-z","volume":"14","author":"CT Solem","year":"2016","unstructured":"Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B (2016) Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes 14:63","journal-title":"Health Qual Life Outcomes"},{"key":"697_CR8","doi-asserted-by":"crossref","unstructured":"Acaster S, Mukuria C, Rowen D, Brazier JE, Wainwright CE, Quon BS et al (2023) Development of the cystic fibrosis questionnaire-Revised-8 dimensions: estimating utilities from the cystic fibrosis questionnaire-revised. Value Health 6:567\u2013578","DOI":"10.1016\/j.jval.2022.12.002"},{"key":"697_CR9","unstructured":"The Pharmaceutical Benefits Advisory Committee (2016) Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee version 5.0. The Pharmaceutical Benefits Advisory Committee"},{"key":"697_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W et al (2020) Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ 21:1245\u20131257","journal-title":"Eur J Health Econ"},{"key":"697_CR11","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","volume":"128","author":"AL Quittner","year":"2005","unstructured":"Quittner AL, Buu A, Messer MA, Modi AC, Watrous M (2005) Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128:2347\u20132354","journal-title":"Chest"},{"key":"697_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s11136-011-0091-5","volume":"21","author":"AL Quittner","year":"2012","unstructured":"Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A et al (2012) Erratum to: psychometric evaluation of the Cystic Fibrosis Questionnaire- Revised in a national, US sample. Qual Life Res 21:1279\u20131290","journal-title":"Qual Life Res"},{"key":"697_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","volume":"42","author":"JE Brazier","year":"2004","unstructured":"Brazier JE, Roberts J (2004) The estimation of a preference-based measure of health from the SF-12. Med Care 42:851\u2013859","journal-title":"Med Care"},{"key":"697_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jcf.2009.04.003","volume":"8","author":"CH Goss","year":"2009","unstructured":"Goss CH, Edwards TC, Ramsey BW, Aitken ML, Patrick DL (2009) Patient-reported respiratory symptoms in cystic fibrosis. J Cyst Fibros 8:245\u2013252","journal-title":"J Cyst Fibros"},{"key":"697_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M et al (2015) Lumacaftor- ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220\u2013231","journal-title":"N Engl J Med"},{"key":"697_CR16","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","volume":"377","author":"JL Taylor-Cousar","year":"2017","unstructured":"Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C et al (2017) Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 377:2013\u20132023","journal-title":"N Engl J Med"},{"key":"697_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J (1992) A power primer. Psychol Bull 112:155\u2013159","journal-title":"Psychol Bull"},{"key":"697_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","volume":"63","author":"LB Mokkink","year":"2010","unstructured":"Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL et al (2010) The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 63:737\u2013745","journal-title":"J Clin Epidemiol"},{"key":"697_CR19","doi-asserted-by":"crossref","unstructured":"De Vet HCW, Terwee CB, Mokkink LB, Knol DL (2011) Measurement in Medicine: a practical guide. Cambridge University Press, pp 1\u2013338","DOI":"10.1017\/CBO9780511996214"},{"key":"697_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/9780470024522","volume-title":"Quality of life: the assessment, analysis and interpretation of patient-reported outcomes","author":"P Fayers","year":"2007","unstructured":"Fayers P, Machin D (2007) Quality of life: the assessment, analysis and interpretation of patient-reported outcomes, 2nd edn. Wiley, Chichester, UK","edition":"2"},{"key":"697_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, Ramos-Go\u00f1i JM, Vilagut G, K\u00f6nig HH (2019) Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ 20:205\u2013216","journal-title":"Eur J Health Econ"},{"key":"697_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40273-017-0546-9","volume":"35","author":"D Rowen","year":"2017","unstructured":"Rowen D, Brazier J, Ara R, Azzabi Zouraq I (2017) The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics 35:33\u201341","journal-title":"PharmacoEconomics"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00697-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00697-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00697-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T08:05:23Z","timestamp":1709107523000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00697-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00697-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For all of the studies contributing data, an ethics committee at each of the trial sites reviewed and approved the protocols. All patients or their parent\/legal guardian provided written informed consent to participate in those studies and for the use of the study data for research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CM reports membership with the EuroQol Group Association and support from Vertex Pharmaceuticals Incorporated for the design, management, and undertaking of all aspects of the study. DR reports funding for the study from Vertex Pharmaceuticals Incorporated. SA reports consulting fees (received by Acaster Lloyd Consulting Ltd from Vertex Pharmaceuticals Incorporated) for the design, analysis, and interpretation of the data. LJM, YL, and PRS report employment with Vertex Pharmaceuticals Incorporated and may own stock or stock options in that company. ALQ has nothing further to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}